Practice Areas

Print PDF

The Myriad Decision — Impact on Entrepreneurship In Diagnostics and Customized Medicines

Yale Biohaven Entrepreneurship Series

March 25, 2014
Yale School of Medicine, New Haven, Connecticut

Cantor Colburn partner Anne Maxwell, Ph.D., joins a CURE panel discussion of the Myriad decision and its Impact on entrepreneurship In diagnostics and customized medicines at the Yale School of Medicine in New Haven on Tuesday, March 25, from 4-6 PM. To register, click here.

In 2013, the Supreme Court, in Association for Molecular Pathology v. Myriad Genetics, unanimously held that naturally occurring DNA is a product of nature and not patentable, but that synthetically-produced complementary DNA (cDNA) is. This BioHaven seminar has convened a panel of experts from various sectors of the biotech and pharmaceutical industry to discuss the business implications of cases such as Myriad.